Showing 16 of 56 recruiting trials for “primary-bone-lymphoma”
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RecruitingNCT06263361 ↗
Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.
👨⚕️ Pietro Mortini, MD, Prof., IRCCS San Raffaele Scientific Institute📍 1 site📅 Started Oct 2021View details ↗
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
Diagnosis; Objective RespOnse; THErApy
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
RecruitingNCT04006561 ↗
Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecruitingNCT05114330 ↗
Secondary Central Nervous System Lymphoma Registry - Charité
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
← PreviousPage 3 of 3
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →